<unk>  is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is sold under the brand names Nitoman and Xenazine among others. On August 15, 2008, the U.S. Food and Drug Administration approved the use of<unk>  to treat chorea associated with Huntington's disease. Although other drugs had been used "off label,"<unk>  was the first approved treatment for Huntington's disease in the U.S. The compound has been known since the 1950s.
Tetrabenazine
Tetrabamate
Tiagabine
Retigabine
Lamotrigine
Mesuximide
Deutetrabenazine
Levetiracetam